Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Takes A New Shot At Alzheimer’s With Cerevance Deal

Pays $25m Upfront

Executive Summary

The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.

You may also be interested in...



As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position

Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.

NeuroDerm Parkinson’s Drug Inches Closer To Market With Phase III Win

Mitsubishi Tanabe Pharma paid $1.1bn to acquire the Israeli biotech in 2017 for a drug that analysts forecast to represent a market opportunity worth up to $1.7bn in peak sales.

Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel